Royal Bank Of Canada Nanobiotix S.A. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.16 - $7.31 $952 - $1,673	229 Added 673.53%	263 $1,000
Q1 2024 Nov 05, 2024	SELL	$6.12 - $8.13 $1,401 - $1,861	-229 Reduced 87.07%	34 $0
Q1 2024 May 15, 2024	SELL	$6.12 - $8.13 $1,658 - $2,203	-271 Reduced 88.85%	34 $0
Q4 2023 Feb 14, 2024	BUY	$5.34 - $9.19 $1,628 - $2,802	305 New	305 $2,000

6.43M

Ticker NBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,875,900
Market Cap $132M
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.